1. Property 1: the insulating binding protein binding TGFB1, wherein the binding protein includes the first polypeptide chain and the second polypeptide chain, both of which have the first and second polypeptide chains, From n-final to c-final (domain name VH) (enlaczador 1) (enlaczador VL) - (enlaczador 2) (enlaczador 2) (bisagra) 8346； - (Fc region) VH domain name includes a main variable heavy complementary region (HCDR1),A critical complementary region of heavy variable 2 (HCDR2) and a critical complementary region of heavy variable 3 (HCDR3),6. Considering that HCB 1 is the amino acid sequence of CAS No. 22, CAS No. 23 is the amino acid sequence of CAS No. 24, CAS No. 25, CAS No. 26 and CAS No. 30； In the VL domain, it includes a variable region (LCDR1) that determines light complementarity,The decision region of one light variable 2 (LCDR2) and one light variable 3 (LCDR3),Chemical Abstracts 1 has the amino acid sequence of Chemical Abstracts 27； Chemical Abstracts 2 has the amino acid sequence of Chemical Abstracts 28； Chemical Abstracts 3 has the amino acid sequence of Chemical Abstracts 29； P is 0 or 1, n is 0 or 1, M is 0 or 1. Requirement 24: an isolated polynucleotide consisting of a nucleoside sequence that encodes binding proteins according to any one of the requirements of 1-23. 13. Claim 33: an ingredient, including any polymer protein of grades 1-23. Claim 37: claimed method 36In this case, the disease or disease is selected from a group consisting of fibrous diseases, cancer, immune system mediated diseases and a combination of these diseases.Reivindicación 1: Una proteína de unión aislada que se une a TGFb1, en donde dicha proteína de unión comprende una primera cadena polipeptídica y una segunda cadena polipeptídica, teniendo ambas cadenas polipeptídicas primera y segunda la fórmula, desde el extremo N-terminal al C-terminal: (dominio VH)-(enlazador 1)ₙ-(dominio VL)-(enlazador 2)ₘ-(bisagra)ₚ-(región Fc) en donde el dominio VH comprende una región
